Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Adaptive Seamless Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Investigate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

Trial Profile

An Adaptive Seamless Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Investigate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jan 2019

At a glance

  • Drugs LNP-023 (Primary)
  • Indications IgA nephropathy
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 19 Nov 2018 Planned End Date changed from 15 Oct 2019 to 6 Apr 2021.
    • 19 Nov 2018 Planned primary completion date changed from 15 Jul 2019 to 12 Jan 2021.
    • 05 Oct 2018 Planned End Date changed from 30 Apr 2019 to 15 Oct 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top